Compare IH & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | SPRO |
|---|---|---|
| Founded | 1996 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5M | 71.6M |
| IPO Year | 2020 | 2017 |
| Metric | IH | SPRO |
|---|---|---|
| Price | $1.23 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.4K | ★ 478.5K |
| Earning Date | 03-31-2026 | 05-13-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $300.00 |
| P/E Ratio | $7.30 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $1.20 | $1.08 |
| 52 Week High | $3.16 | $3.08 |
| Indicator | IH | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 39.88 |
| Support Level | N/A | $1.18 |
| Resistance Level | $1.42 | $1.29 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 11.11 | 52.63 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.